Table 3

Structural disease progression in patients with early RA who received DMARDs and the entire ESPOIR cohort.

SD-treated patients

All ESPOIR patients


All patients

(number = 370)

(number = 736a)

- ΔvSHS total

1.6 ± 5.5 (0)

0.96 ± 4.4 (0)

- ΔvSHS erosion

1.5 ± 4.7 (0)

0.96 ± 3.8 (0)

- ΔvSHS narrowing

0.2 ± 1.8 (0)

0.01 ± 1.81 (0)

Patients with structural progressionb

(number = 126, 34.1%)

(number = 187, 25.4%)

- ΔvSHS total

5.4 ± 7.0 [54]

5.0 ± 6.3 [54]

- ΔvSHS ≥ 5 points (RRP)

41 (11.1%)

58 (7.9%)


Data are mean ± SD (median) or number (%).aX-ray data were available for only 736 patients; bStructural progression was defined as ΔvSHS ≥ 1 point (that is, the smallest detectable difference). DMARD, disease-modifying anti-rheumatic drugs; RRP, rapid radiographic progression; SD, synthetic DMARD; ΔvSHS, change in van der Heijde-modified Sharp score.

Fautrel et al. Arthritis Research & Therapy 2012 14:R249   doi:10.1186/ar4092

Open Data